Here are the DEF 14A proxy statements from Intelligent Bio Solutions Inc. (INBS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow INBS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INBS filings page.
Intelligent Bio Solutions Inc. (INBS) is asking stockholders to approve, for Nasdaq Listing Rule 5635(d) purposes, issuance of up to 2,036,659 common shares upon exercise of Series N-2 Warrants issued in a private placement on September 2, 2026. Its virtual annual meeting is scheduled for December 3, 2026; stockholders of record on October 13, 2026, may vote, and 3,316,803 common shares were issued and outstanding and entitled to vote on that record date.
The agenda also includes election of four directors, ratification of UHY LLP as independent auditor for fiscal 2027, an amendment and restatement of the 2019 Plan effective December 3, 2026, advisory executive-pay and pay-frequency votes, and two conditional adjournment authorizations to seek votes for the plan and Nasdaq proposals. The Board recommends a one-year interval for future executive-pay votes and recommends FOR the other listed proposals. Each share carries one vote, and one-third of the issued and outstanding shares entitled to vote constitutes a quorum. Fiscal 2026 total compensation was $661,332 for President and CEO Harry Simeonidis and $521,500 for CFO Spiro Sakiris.